Caprion

Accelerating precision medicine™

Web News

September 25, 2020

UPCOMING WEBINAR:
Should Assessing T-Cell Response Be an Essential Part of COVID-19 Vaccine Development?

Insights on Vaccine Development from Key Opinion Leaders

WEBINAR co-sponsored by

Logo WCG

Thursday Oct 1st | 1-2pm ET

REGISTER

While discussions of COVID-19 immune responses, including those in early vaccine clinical studies, focus largely on antibody response, recent data indicate that the cellular immune response is also essential to consider. Assessing T-cell responses can provide critical information about vaccine development and persistence of protective immunity against SARS-CoV-2 that are critical to combat the pandemic.

In this webinar, our speakers will discuss:

  • An overview of the current state of COVID-19 vaccine development
  • The adaptive immune response to SARS-CoV-2 and the importance of cellular immunity
  • Testing methods and assay standardization for understanding complex immune system reactions as part of vaccine development programs

Our speakers:

Scott Gottlieb

Scott Gottlieb, M.D., Former Commissioner of the Food and Drug Administration (FDA)
Dr. Gottlieb will discuss the implications of immune response testing for overall assessment, regulatory approval, and public acceptance of COVID-19 vaccines.

James Rothman

James Rothman, Ph.D., Sterling Professor of Cell Biology, Yale University; Recipient, Nobel Prize in Medicine, 2013
Dr. Rothman will provide an overview of the immune response to SARS-CoV-2 and the importance of cellular immunity. The key findings from our previous experiences with SARS-CoV-1 as well as the latest publications will also be discussed.

Eustache Paramithiotis

Eustache Paramithiotis, Ph.D., Vice President, Research & Development, Caprion-HistoGeneX
Testing methods for understanding complex immune system reactions as part of vaccine development programs will be discussed by Dr. Paramithiotis. Information on the methodology and accuracy of these assays will be provided.


Moderator: Lindsay McNair, M.D., M.P.H., MS Bioethics, Chief Medical Officer, WCG




March 20, 2020

COVID-19 Outbreak Update

At Caprion-HistoGeneX, our top priority is the health and safety of our employees, our partners and our clients. Just like you, our team follows the COVID-19 pandemic closely to ensure rapid response as the situation evolves. As we remain committed to ensuring our clients and partners can continue moving their research forward, we have taken different steps to mitigate risks and ensure our continued support around the world. Here is some information about these measures:

  • We have implemented an internal policy ensuring that our employees respect all the measures required to minimize the risk of infection and dissemination within our facilities, including social distancing and good hygiene practices, based on WHO and local recommendations
  • All employees who can do so are required to work from home
  • Access to our facilities is restricted to our employees and to suppliers whose services are absolutely required to maintain our activities
  • All non-essential business travels have been cancelled and employees returning from a trip are self-isolating at home
  • Operational teams are split through different workspace or work shifts, whenever possible to reduce risk
  • We are in close communication with our suppliers to ensure a continuous supply of all critical material and reagents.

Our management team meets daily to monitor the situation and adapt our mitigation plan to help “flattening the curve” while reducing disruptions for our clients.

All our laboratories are currently operational, and we remain committed to continuing to support our partners during these critical times and hope you and your loved ones are and will remain safe.

For any questions, please contact our business development team or email at info@caprion.com


Sincerely,

Martin LeBlanc
President & CEO
Caprion Biosciences-HistoGeneX


Caprion

Accreditations & Certifications

CAP accreditation and CLIA certification

CAP Accredited

Headquarters

+1 514.360.3600
+1 877.776.3443
141 President Kennedy Ave., Suite SB-5658
Montreal, Quebec
CANADA

USA

Primity Bio
48383 Fremont Blvd
Suite 118
Fremont, CA 94538
Tel.: +1 858.229.2529

Serametrix
2235 Farraday Ave,Suite N,
Carlsbad, CA, 92008, USA
Tel: +1 760 652 4060

HistoGeneX
1331 W 75th St #401,
Naperville, IL 60540, USA
Tel: +1 630-473-6655
info@histogenex.com

AUSTRALIA

Serametrix Party Limited
Suite 4/54-60 Briggs Street
Camperdown, NSW, 2050
Australia
+61 2 9168 5908

EUROPE

Caprion Biosciences Inc.
+32 (0) 71 96 23 36
8 rue Adrienne Bolland
6041 Gosselies
BELGIUM

Serametrix
Unit 22, Surrey Technology Centre,
40 Occam Road,
Guildford, Surrey, UK
GU2 7YG
Tel: +44 1483 685599

Antwerp, Belgium
HistoGeneX
Sint-Bavostraat 78
2610 Antwerpen (Wilrijk)
Belgium
Tel: +32 3 50 20 500
Sample Reception: +32 3 50 20 620
Shipments: +32 3 50 20 625

CANADA LAB

201 President Kennedy Ave., Suite PK-3900
Montreal, Quebec
CANADA
+1 514.360.3600
+1 877.776.3443



Follow us

        

Contact

+1 877.776.3443

info@caprion.com